1-6 of 6
Nozomu Muraishi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Available to Purchase
Subject Area:
Oncology
Kazuto Tajiri, Kenichiro Tsukada, Yoshiharu Tokimitsu, Yuchi Motofuji, Kengo Kawai, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Yukihiro Shimizu, Ichiro Yasuda
Journal: Oncology
Oncology (2024) 102 (2): 131–140.
https://doi.org/10.1159/000533952
Published Online: 04 September 2023
View articletitled, Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Open the PDF for Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma in another window
Journal Articles

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis

Open Access
Subject Area:
Karger e-Journal Backfile Collection 2023 , Oncology
Nozomu Muraishi, Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Ichiro Yasuda, Hiromitsu Kumada
Journal: Oncology
Oncology (2023) 101 (2): 134–144.
https://doi.org/10.1159/000526976
Published Online: 14 September 2022
View articletitled, The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis
Open the PDF for The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis in another window
Journal Articles

Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

Open Access
Subject Area:
Oncology
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Nozomu Muraishi, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Hiromitsu Kumada
Journal: Oncology
Oncology (2022) 100 (6): 320–330.
https://doi.org/10.1159/000523850
Published Online: 01 March 2022
View articletitled, Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
Open the PDF for Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Open Access
Subject Area:
Oncology
Norio Akuta, Yusuke Kawamura, Fumitaka Suzuki, Satoshi Saitoh, Yasuji Arase, Nozomu Muraishi, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yoshiyuki Suzuki, Kenji Ikeda, Hiromitsu Kumada
Journal: Oncology
Oncology (2022) 100 (1): 31–38.
https://doi.org/10.1159/000519995
Published Online: 17 November 2021
View articletitled, Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage
Open the PDF for Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage in another window
Journal Articles

Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment

Open Access
Subject Area:
Oncology
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Yuta Kobayashi, Satoshi Okubo, Nozomu Muraishi, Soichi Iritani, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Hiromitsu Kumada
Journal: Oncology
Oncology (2021) 99 (10): 611–621.
https://doi.org/10.1159/000516565
Published Online: 17 June 2021
View articletitled, Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment
Open the PDF for Pretreatment Positron Emission Tomography with 18 F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment in another window
Journal Articles

Potential and Clinical Significance of 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment

Open Access
Subject Area:
Oncology
Daiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Yuta Kobayashi, Satoshi Okubo, Nozomu Muraishi, Akira Kajiwara, Soichi Iritani, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Hiromitsu Kumada
Journal: Oncology
Oncology (2021) 99 (3): 169–176.
https://doi.org/10.1159/000510754
Published Online: 18 November 2020
View articletitled, Potential and Clinical Significance of 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment
Open the PDF for Potential and Clinical Significance of 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment in another window